Faruqi & Faruqi, LLP Announces Investigation of Illumina, Inc.

Faruqi & Faruqi, LLP is investigating the conduct of the Board of Directors of Illumina for potential breaches of fiduciary duties in connection with their rejection of Roche Holding AG’s offer to purchase Illumina.
By: Faruqi & Faruqi, LLP
 
Feb. 8, 2012 - PRLog -- Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Illumina, Inc. (“Illumina” or the “Company”)  for potential breaches of fiduciary duties in connection with their rejection of Roche Holding AG’s (“Roche”) offer to purchase Illumina for $44.50 per share in cash, or an aggregate of approximately $5.7 billion on a fully diluted basis.  

Request more information now by clicking here: www.faruqilaw.com/ILMN

On January 25, 2012, Roche announced that it would acquire all outstanding shares of the Company for $44.50 per share. This offer represents a 64% premium over Illumina’s stock price on December 21, 2011, the day before market rumors about a potential transaction between Roche and Illumina drove Illumina’s stock price significantly higher, a 61% premium over the one-month historical average and a 43% premium over the three-month historical average of Illumina’s share price, both as of December 21, 2011.  It also represents a 30.1x multiple of Illumina’s projected forward earnings based upon analysts’ current consensus estimates for 2012.  On February 7, 2012, rather than considering the premium being offered to shareholders or negotiating for a higher bid, Illumina’s board unanimously rejected Roche’s offer as “grossly inadequate.”    

The Company’s refusal to engage in any meaningful negotiations or any substantive dialogue with Roche concerning the proposed acquisition of Illumina at a premium price is the key focus of this investigation.

Faruqi & Faruqi, LLP is a national law firm which represents investors and individuals in class action litigation.  The firm is focused on providing exemplary legal services in complex litigation in the areas of securities, shareholder, antitrust and consumer litigation, throughout all phases of litigation.  The firm has an experienced trial team which has achieved significant victories on behalf of the firm’s clients.

If you own common stock in Illumina and wish to obtain additional information, please visit us at www.faruqilaw.com/ILMN or contact Juan E. Monteverde, Esq. either via e-mail at jmonteverde@faruqilaw.com or by telephone at (877) 247-4292 or (212) 983-9330.  

Contact:

Faruqi & Faruqi, LLP
369 Lexington Avenue, 10th Floor
New York, NY 10017
Attn: Juan E. Monteverde, Esq.
jmonteverde@faruqilaw.com
Toll Free: (877) 247-4292
Phone:     (212) 983-9330

Attorney Advertising. (C) 2011 Faruqi & Faruqi, LLP.  The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com).  Prior results do not guarantee or predict a similar outcome with respect to any future matter.  We are happy to discuss your particular case.

SOURCE: Faruqi & Faruqi, LLP
End
Source:Faruqi & Faruqi, LLP
Email:***@faruqilaw.com
Posted By:***@faruqilaw.com Email Verified
Industry:Biotech, Health, Technology
Subject:Services
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
? PRs
Trending News
Most Viewed
Top Daily News



Like PRLog?
9K2K1K
Click to Share